UBS (NYSE:UBS) initiated coverage of Accretive Health (NYSE:AH) with a rating of Buy and a price target of $29. The shares recently traded at $23.04, up $0.89 or 4.02%, on the day. The shares have traded in a 52-week range of $8.30 to $32.82 and its market capitalization is $2.25 billion. About the company: Accretive Health, Inc. offers health care revenue cycle consulting services. The Company helps its customers avoid bad debt write-offs, uncompensated care, payor denials and corresponding administrative write-offs, and lost revenue for missed charges.
(Note: Stock ratings are sourced from Briefing.com via the Wall St. Journal. Selected financial data are sourced from Google Finance. All data are assumed to be accurate.)
Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>